Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†☆
- PMID: 33221366
- DOI: 10.1016/j.annonc.2020.11.002
Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†☆
Keywords: Clinical Practice Guidelines; Myelodysplastic syndromes; diagnosis; follow-up; treatment.
Conflict of interest statement
Disclosure PF has received honoraria and/or research support from Celgene, Janssen, AbbVie, Jazz, Novartis, Roche and Aprea; GFS has received honoraria from and/or played an advisory role for AbbVie, Amgen, Böehringer Ingelheim, Celgene, Helsinn Healthcare, Roche, Janssen-Cilag, Novartis, Takeda and Onconova; VS has received honoraria from Astex, Celgene, Novartis, Pfizer, Janssen-Cilag and Takeda; UP has received honoraria and/or research support from Celgene, Janssen, AbbVie, Jazz, Novartis and Amgen; DH has received honoraria from Celgene, Novartis and Takeda, and research support from Novartis and Celgene; UM has reported honoraria from Celgene, Roche and Amgen.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical